|

Revumenib Clinical Trials

11 actively recruiting trials across 7 locations

Also known as: Menin-MLL Inhibitor SNDX-5613, Menin-MLL Interaction Inhibitor SNDX-5613, Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor SNDX-5613, SNDX 5613, SNDX- 5613, SNDX-5613, SNDX5613, Trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2- yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

Duarte, California3 trials

A Study of Revumenib and Mezigdomide in People With Leukemia

City of Hope Cancer Center (Data collection only)

Phase 1/2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

City of Hope Comprehensive Cancer Center

Phase 1/2
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

City of Hope Medical Center

Phase 1

Other2 trials

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Phase 3
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Phase 3

Orange, California1 trial

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 1

San Diego, California1 trial

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Rady Children's Hospital

Phase 1

Baltimore, Maryland1 trial

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Johns Hopkins University

Phase 1/2

Boston, Massachusetts1 trial

Revumenib in Combination With 7+3 + Midostaurin in AML

Brigham and Women's Hospital

Phase 1

New York, New York1 trial

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Memorial Sloan Kettering Cancer Center

Phase 2

Chapel Hill, North Carolina1 trial

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

UNC Hospitals, University of North Carolina at Chapel Hill

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.